Innate Pharma
IPHA
6 hedge funds and large institutions have $6.36M invested in Innate Pharma in 2020 Q3 according to their latest regulatory filings, with funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 1 closing their positions.
1.51% less ownership
Funds ownership: 3.64% → 2.13% (-1.5%)
14% less funds holding
Funds holding: 7 → 6 (-1)
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
69% less capital invested
Capital invested by funds: $20.3M → $6.36M (-$13.9M)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$28.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCMNY
Rubric Capital Management (New York)
New York
|
-$3.87M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
-$3.42M |
| 3 |
Morgan Stanley
New York
|
-$61.7K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Wellington Management Group
Boston,
Massachusetts
| $5.39M | +$28.7K | +5,059 | +0.4% |
|
|
RCMNY
2
Rubric Capital Management (New York)
New York
| $960K | -$3.87M | -681,673 | -73% |
|
3
Osaic Holdings
Scottsdale,
Arizona
| $8K | – | – | – |
|
|
4
Morgan Stanley
New York
| $6K | -$61.7K | -10,870 | -87% |
|
|
SPIA
5
Steward Partners Investment Advisory
New York
| $4K | – | – | – |
|
6
Millennium Management
New York
| $288 | – | – | – |
|
|
7
Adage Capital Partners
Boston,
Massachusetts
| – | -$3.42M | -500,000 | Closed |
|
IPHA Hedge Fund Activity: Q3 2020 in Review
6 of the 4,957 institutional investors tracked by Wall St. Rank reported a position in Innate Pharma (IPHA) for Q3 2020, worth a combined $6.36M — down 69% from $20.3M a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of IPHA and 0 opened new positions — a net loss of 1 holder — while 2 trimmed existing stakes and 1 added.
The largest buyer was Wellington Management Group, adding an estimated $28.7K. The largest seller was Rubric Capital Management (New York), cutting an estimated $3.87M.
- 6 institutional investors held Innate Pharma (IPHA) as of Q3 2020, down from 7 in Q2 2020.
- Funds reported $6.36M of Innate Pharma stock for Q3 2020, down 69% quarter-over-quarter.
- 0 funds opened new Innate Pharma positions in Q3 2020 and 1 closed out, a net change of -1 holder.
- The largest Innate Pharma buyer in Q3 2020 was Wellington Management Group, an estimated $28.7K added.
- The largest Innate Pharma seller in Q3 2020 was Rubric Capital Management (New York), an estimated $3.87M sold.
Based on aggregated 13F filings for Q3 2020.